The Max Foundation is pleased to welcome Curt Malloy as the newest member of our Executive Board. Curt, a fellow advocate for people facing cancer around the world, has been a strong supporter of our work for many years throughout his active engagement in global health.
Curt currently serves as the Chief Operating Officer at Cancer Research And Biostatistics (CRAB) in Seattle, where he leads data management, project management, clinical monitoring, and regulatory. He is a co-leader of CRAB’s Latin America Initiative, which was formed with the intention of providing clinical research training programs for clinical investigators and statisticians in Latin America and identifying clinical research opportunities.
Prior to joining CRAB, Curt was the operational leader for the Fred Hutch Vaccine and Infectious Disease Division, while also serving on the boards of their global research initiatives in South Africa, Uganda, and China. Prior to the Fred Hutch, Curt served for ten years in various leadership positions at the Infectious Disease Research Institute. Curt has a Masters of Public Health from Columbia University School of Public Health and earned a Juris Doctor with a focus on intellectual property from Seattle University School of Law. He is fluent in Spanish and is particularly passionate about Latin America, social and health equity and planetary health.
Pat Garcia-Gonzalez, CEO of The Max Foundation said of Curt’s appointment, “It is well known that The Max Foundation has a strong historical connection to Latin America given that helping families there was the focus of our original mission. Curt has an impressive background that promises to only strengthen our resolve in serving cancer patients in Latin America and across the globe.”
We are thrilled to be able to leverage Curt’s deep experience serving on NGO boards, his expertise in the field of cancer research, and his strong commitment to global health—all to bring dignity and hope to people facing cancer around the world.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Estoril, Portugal– In recognition of her personal contribution and role in leading The Max Foundation in increasing access to treatment, care, and support for people living with cancer around the world, Max CEO, Pat Garcia-Gonzalez is the first recipient of the International Chronic Myeloid Leukemia (CML) Foundation’s ERSAP Prize. The International CML Foundation awarded our….
Armenia and Nepal are the first of 29 countries to receive CLL treatment SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and….
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….
